Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment

CD40-activating immunotherapy has potent antitumor effects due to its ability to activate dendritic cells and induce cytotoxic T-cell responses. However, its efficacy is limited by immunosuppressive cells in the tumor and by endothelial anergy inhibiting recruitment of T-cells. Here, we show that co...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hooren, Luuk, Georganaki, Maria, Huang, Hua, Mangsbo, Sara M., Dimberg, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226582/
https://www.ncbi.nlm.nih.gov/pubmed/27385210
http://dx.doi.org/10.18632/oncotarget.10364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226582/
https://www.ncbi.nlm.nih.gov/pubmed/27385210
http://dx.doi.org/10.18632/oncotarget.10364

Ejemplares similares